MannKind Corporation

MannKind Corporation is a biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic and orphan lung diseases. MannKind Corporation’s current product portfolio includes Afrezza, an inhaled insulin for adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous insulin infusion. The company also markets Tyvaso DPI for pulmonary arterial hypertension and pulmonary hypertension, extending its presence in specialty respiratory care. MannKind Corporation serves patients and healthcare providers across endocrine and lung disease markets, with products designed to address chronic conditions that require convenient, patient-centered treatment options. Headquartered in Danbury, Connecticut, MannKind Corporation operates as a focused healthcare business centered on innovative drug delivery and disease management solutions.

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Michael E. Castagna Pharm.D.

Employees

591

Headquarters

Danbury, CT, United States

Website

mannkindcorp.com